AU2013351180A1 - Combination therapy with volasertib - Google Patents

Combination therapy with volasertib Download PDF

Info

Publication number
AU2013351180A1
AU2013351180A1 AU2013351180A AU2013351180A AU2013351180A1 AU 2013351180 A1 AU2013351180 A1 AU 2013351180A1 AU 2013351180 A AU2013351180 A AU 2013351180A AU 2013351180 A AU2013351180 A AU 2013351180A AU 2013351180 A1 AU2013351180 A1 AU 2013351180A1
Authority
AU
Australia
Prior art keywords
day
aml
effective amount
volasertib
treatment cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013351180A
Other languages
English (en)
Inventor
Tillmann Taube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2013351180A1 publication Critical patent/AU2013351180A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
AU2013351180A 2012-11-30 2013-11-27 Combination therapy with volasertib Abandoned AU2013351180A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12195162 2012-11-30
EP12195162.8 2012-11-30
PCT/EP2013/074862 WO2014083058A1 (en) 2012-11-30 2013-11-27 Combination therapy with volasertib

Publications (1)

Publication Number Publication Date
AU2013351180A1 true AU2013351180A1 (en) 2015-04-30

Family

ID=47325907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013351180A Abandoned AU2013351180A1 (en) 2012-11-30 2013-11-27 Combination therapy with volasertib

Country Status (15)

Country Link
US (2) US20140154304A1 (enExample)
EP (1) EP2925343A1 (enExample)
JP (1) JP2016501208A (enExample)
KR (1) KR20150090091A (enExample)
CN (1) CN104812400A (enExample)
AU (1) AU2013351180A1 (enExample)
BR (1) BR112015011748A2 (enExample)
CA (1) CA2889787A1 (enExample)
CL (1) CL2015001258A1 (enExample)
EA (1) EA201500579A1 (enExample)
IL (1) IL238174A0 (enExample)
IN (1) IN2015DN03075A (enExample)
MX (1) MX2015006592A (enExample)
PH (1) PH12015501113A1 (enExample)
WO (1) WO2014083058A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104306336B (zh) * 2014-11-18 2016-08-24 河北天成药业股份有限公司 枸橼酸柔红霉素脂质体注射液的制备工艺
JP6976941B2 (ja) * 2015-11-11 2021-12-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法
US20230201202A1 (en) * 2020-05-27 2023-06-29 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN116785296B (zh) * 2023-06-06 2025-09-05 河北渤腾医药技术有限公司 一种plk1的抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20050735B1 (hr) 2003-02-26 2013-08-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Dihidropteridinoni, metoda za njihovu proizvodnju i upotrebu u obliku lijekova
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
RU2474427C2 (ru) * 2006-12-20 2013-02-10 Универзитетсклиникум Хамбург-Эппендорф Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей
US8092828B2 (en) * 2007-02-16 2012-01-10 Celator Pharmaceuticals, Inc. Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
US9358233B2 (en) * 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia

Also Published As

Publication number Publication date
CL2015001258A1 (es) 2015-10-02
EA201500579A1 (ru) 2015-12-30
US20140154304A1 (en) 2014-06-05
EP2925343A1 (en) 2015-10-07
WO2014083058A1 (en) 2014-06-05
IL238174A0 (en) 2015-05-31
PH12015501113A1 (en) 2015-08-17
US20170173023A1 (en) 2017-06-22
CA2889787A1 (en) 2014-06-05
BR112015011748A2 (pt) 2017-07-11
KR20150090091A (ko) 2015-08-05
MX2015006592A (es) 2015-08-05
JP2016501208A (ja) 2016-01-18
CN104812400A (zh) 2015-07-29
IN2015DN03075A (enExample) 2015-10-02

Similar Documents

Publication Publication Date Title
US9358233B2 (en) Method for treating acute myeloid leukemia
US20170173023A1 (en) Combination therapy with volasertib
US11622965B2 (en) Methods for treating lymphoid malignancies
JP7783217B2 (ja) アズブジンを含む抗腫瘍医薬組成物
EP4424316B1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
JP2023512724A (ja) リンパ腫の治療におけるピリド［１，２－ａ］ピリミジノン化合物の使用
US20190240242A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
US20150031642A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i
US20230372382A1 (en) Use of adenosine diphosphate ribose for adjuvant therapy with radiation and/or anti-cancer treatment
EP3200879B1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
Poston et al. Controversies regarding use of myeloid growth factors in leukemia
KR20220100006A (ko) 다중 표적 단백질 키나제 억제제의 용도
EP4085908A1 (en) Pharmaceutical combination for treating tumors and application thereof
AU2023315150A1 (en) Cancer combination therapy including a flt3-inhibitor
Dittrich et al. Therapy of the small cell lung cancer—Comparison two established chemotherapy regime (ACO vs. CEV)

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application